MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In


News Categories




Physicians Expect Xtandi (Enzalutamide) to Become Treatment Leader for Metastatic Prostate Cancer

Survey finds rapid uptake since product launch (May 6)

BioTrends Research Group, a research and advisory firm located in Exton, Penn., finds that, at 6 months after the launch of Xtandi (enzalutamide, Astellas Pharma/Medivation), surveyed urologists and medical oncologists prescribed the drug to 19% and 24% of their metastatic castrate-resistant prostate cancer (mCRPC) patients who failed to respond to or had rapid progression after treatment with Taxotere (docetaxel, Sanofi; generics).

In 6 months’ time, surveyed respondents expect to prescribe Xtandi to 35% to 39% of these mCRPC patients, making the drug the patient-share leader in this population.

The survey also finds that 30% of surveyed urologists have prescribed Xtandi in clinical practice, compared with 43% of surveyed medical oncologists. In contrast, data published 1 month after the launch of Xtandi showed that less than 10% of surveyed urologists had prescribed the drug in clinical practice (i.e., outside of clinical trials), compared with 39% of medical oncologists.

Key reasons cited by surveyed respondents for not having prescribed Xtandi included lack of familiarity with the drug and the fact that many eligible patients were already receiving Zytiga (abiraterone, Johnson & Johnson/Janssen Biotech). However, most of current non-prescribing urologists (61%) and medical oncologists (88%) said that they expect to prescribe Xtandi within the next 6 months.

“Xtandi is experiencing rapid uptake within its FDA-approved indication for docetaxel-pretreated mCRPC, and its inclusion on National Comprehensive Cancer Network guidelines for use in chemotherapy-naive, asymptomatic mCRPC patients who are not candidates for docetaxel is spurring its use in this earlier disease setting,” said analyst Rachel Webster, DPhil. “While more than half of surveyed physicians report decreased use of Jevtana (Sanofi’s cabazitaxel) in their docetaxel-pretreated mCRPC patients, more than half of surveyed respondents currently report no change in their use of Zytiga in this setting.”

Source: BioTrends Research Group; May 6, 2013.

More stories